GSK - GSK plc (GSK) TD Cowen 44th Annual Health Care Conference (Transcript)
2024-03-11 12:54:07 ET
GSK plc (GSK)
TD Cowen 44th Annual Health Care Conference
March 4, 2024, 2:50 pm ET
Company Participants
Luke Miels - CCO
Conference Call Participants
Stephen Scala - TD Cowen
Presentation
Stephen Scala
Well, good afternoon, and welcome once again. We're delighted to have GSK here at the 44th Annual Cowen Health Care Conference. Representing the company is Luke Miels, who is the Chief Commercial Officer. Lots to talk about today, lots of exciting dynamics at GSK. So we're just going to dive right in.
Question-and-Answer Session
Q - Stephen Scala
And we'll start with a product that’s been a huge success over the last few years that's Shingrix. I think that the latest guidance from the company is that peak sales would be £4 billion plus, but the product is on a trajectory to do that this year. So how should we think about that guidance? Why isn't a better guidance £6 billion, £8 billion? And why are those numbers not realistic?
Luke Miels
Sure. Yes, I mean, I think you got to break it into three buckets. So you've got the U.S., where we’re picking up at about 1% every quarter in terms of penetration into the labeled population. But the deeper you go, of course, the less motivated those individuals are to achieve vaccinations. So we're having to evolve our targeting strategy and we still think there's room there within the U.S....
GSK plc (GSK) TD Cowen 44th Annual Health Care Conference (Transcript)